Biosev announced consolidated earnings results for the first quarter ended June 30, 2017. For the quarter, the company reported net revenue of BRL 1,832,242,000 compared to BRL 1,672,682,000 a year ago. Operating expenses were BRL 204,947,000 compared to BRL 139,586,000 a year ago. Loss before taxes on income was BRL 861,243,000 compared to BRL 47,870,000 a year ago. Net loss was BRL 577,303,000 compared to BRL 353,307,000 a year ago. Net cash used in operating activities was BRL 62,568,000 compared to BRL 1,286,092,000 a year ago. Increase in property, plant and equipment was BRL 120,238,000 compared to BRL 135,146,000 a year ago. Additions to biological assets were BRL 134,362,000 compared to BRL 104,088,000 a year ago. Increase in intangible assets was BRL 547,000 compared to BRL 954,000 a year ago. Adjusted EBITDA was BRL 158,976,000 compared to BRL 140,019,000 a year ago. Total CapEx was BRL 266,705,000 compared to BRL 250,504,000 a year ago. As at June 30, 2017, the company's net debt was BRL 5,218 million.

The company provided CapEx guidance for the fiscal year 2018. For the year, the company expects CapEx of BRL 1,355 million to BRL 1,250 million.